Capa/PortadaYahoo FinancePortadaWhy Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib DataRRedacciónRedação · anteayerLeitura 2 minLer a nota completa em Yahoo Finance